SMYD2在恶性肿瘤中的研究进展

doi:10.11904/j.issn.1002-3070.2022.03.015

摘要/Abstract

摘要： 赖氨酸甲基转移酶2(Lysine methyltransferase 2,SMYD2)是一类特殊的赖氨酸甲基转移酶,包含SET(Suppressor of variegation,Enhancer of zeste,Trithorax)结构域和MYND(Myeloid-nervy-deaf1)结构域。通过对组蛋白和其他蛋白的翻译后修饰,SMYD2在表观遗传、机体发育和癌变中发挥关键作用。近年来,SMYD2在恶性肿瘤中的作用日益受到关注。多项研究表明,SMYD2在卵巢癌、乳腺癌、结肠癌、肾细胞癌等恶性肿瘤的发生发展以及转移过程中发挥重要作用。本文对近年来SMYD2在恶性肿瘤中的研究进展进行阐述。

关键词: 赖氨酸甲基转移酶2, 肿瘤, 高表达, 甲基化

Abstract: Lysine methyltransferase 2(SMYD2)is a kind of special lysine methyltransferase containing SET(Suppressor of variegation,Enhancer of zeste,Trithorax)domain and MYND(Myeloid-nervy-deaf1)domain.Through post-translational modifications of histones and other proteins,SMYD2 plays a key role in epigenetics,body development,and carcinogenesis.In recent years,the role of SMYD2 in malignant tumors has received increasing attention.A number of studies have shown that SMYD2 plays an important role in the occurrence,development and metastasis of ovarian cancer,breast cancer,colon cancer,renal cell carcinoma and other malignant tumors.This article describes the research progress of SMYD2 in malignant tumors in recent years.

Key words: Lysine methyltransferase 2, Tumor, High expression, Methylation

中图分类号:

R737.3

杨楠, 王棹, 张玉, 张云艳. SMYD2在恶性肿瘤中的研究进展[J]. 实用肿瘤学杂志, 2022, 36(3): 273-277.

YANG Nan, WANG Zhao, ZHANG Yu, ZHANG Yunyan. Research progress of SMYD2 in malignant tumors[J]. Journal of Practical Oncology, 2022, 36(3): 273-277.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/10.11904/j.issn.1002-3070.2022.03.015

http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/Y2022/V36/I3/273

参考文献

1 Zhang B,Liao L,Wu F,et al.Synthesis and structure-activity relationship studies of LLY-507 analogues as SMYD2 inhibitors[J].Bioorg Med Chem Lett,2020,30(22):127598.
2 Leinhart K,Brown M.SET/MYND lysine methyltransferases regulate gene transcription and protein activity[J].Genes(Basel),2011,2(1):210-218.
3 Chandramouli B,Melino G,Chillemi G.SMYD2 conformational changes in response to p53 binding:role of the C-terminal domain[J].Mol Oncol,2019,13(6):1450-1461.
4 Brown MA,Sims RJ,Gottlieb PD,et al.Identification and characterization of SMYD2:a split SET/MYND domain-containing histone H3 lysine 36-specific methyltransferase that interacts with the Sin3 histone deacetylase complex[J].Mol Cancer,2006,5:26.
5 Wu J,Cheung T,Grande C,et al.Biochemical characterization of human SET and MYND domain-containing protein 2 methyltransferase[J].Biochemistry,2011,50(29):6488-6497.
6 Spellmon N,Sun X,Sirinupong N,et al.Molecular dynamics simulation reveals correlated inter-Lobe motion in protein lysine methyltransferase SMYD2[J].PLoS One,2015,10(12):e0145758.
7 Bannister AJ,Schneider R,Myers FA,et al.Spatial distribution of di-and tri-methyl lysine 36 of histone H3 at active genes[J].J Biol Chem,2005,280(18):17732-17736.
8 Rao B,Shibata Y,Strahl BD,et al.Dimethylation of histone H3 at lysine 36 demarcates regulatory and nonregulatory chromatin genome-wide[J].Mol Cell Biol,2005,25(21):9447-9459.
9 Abu-Farha M,Lambert JP,Al-Madhoun AS,et al.The tale of two domains:proteomics and genomics analysis of SMYD2,a new histone methyltransferase[J].Mol Cell Proteomics,2008,7(3):560-572.
10 Fan JD,Lei PJ,Zheng JY,et al.The selective activation of p53 target genes regulated by SMYD2 in BIX-01294 induced autophagy-related cell death[J].PLoS One,2015,10(1):e0116782.
11 Saddic LA,West LE,Aslanian A,et al.Methylation of the retinoblastoma tumor suppressor by SMYD2[J].J Biol Chem,2010,285(48):37733-37740.
12 Obermann WMJ.A motif in HSP90 and P23 that links molecular chaperones to efficient estrogen receptor alpha methylation by the lysine methyltransferase SMYD2[J].J Biol Chem,2018,293(42):16479-16487.
13 Sung H,Ferlay J,Siegel RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin,2021,71(3):209-249.
14 Engqvist H,Parris TZ,Kovacs A,et al.Validation of novel prognostic biomarkers for early-stage clear-cell,endometrioid and mucinous ovarian carcinomas using immunohistochemistry[J].Front Oncol,2020,10:162.
15 Kojima M,Sone K,Oda K,et al.The histone methyltransferase SMYD2 is a novel therapeutic target for the induction of apoptosis in ovarian clear cell carcinoma cells[J].Oncol Lett,2020,20(5):153.
16 Kukita A,Sone K,Oda K,et al.Histone methyltransferase SMYD2 selective inhibitor LLY-507 in combination with poly ADP ribose polymerase inhibitor has therapeutic potential against high-grade serous ovarian carcinomas[J].Biochem Biophys Res Commun,2019,513(2):340-346.
17 Song J,Liu Y,Chen Q,et al.Expression patterns and the prognostic value of the SMYD family members in human breast carcinoma using integrative bioinformatics analysis[J].Oncol Lett,2019,17(4):3851-3861.
18 Liu L,Kimball S,Liu H,et al.Genetic alterations of histone lysine methyltransferases and their significance in breast cancer[J].Oncotarget,2015,6(4):2466-2482.
19 Li LX,Zhou JX,Calvet JP,et al.Lysine methyltransferase SMYD2 promotes triple negative breast cancer progression[J].Cell Death Dis,2018,9(3):326.
20 Lai Y,Yang Y.SMYD2 facilitates cancer cell malignancy and xenograft tumor development through ERBB2-mediated FUT4 expression in colon cancer[J].Mol Cell Biochem,2020,10:1007.
21 Meng F,Liu X,Lin C,et al.SMYD2 suppresses APC2 expression to activate the Wnt/|-catenin pathway and promotes epithelial-mesenc hymal transition in colorectal cancer[J].Am J Cancer Res,2020,10(3):997-1011.
22 Ren H,Wang Z,Chen Y,et al.SMYD2-OE promotes oxaliplatin resistance in colon cancer through MDR1/P-glycoprotein via MEK/ERK/AP1 pathway[J].Onco Targets Ther,2019,12:2585-2594.
23 Pires-Luis AS,Vieira-Coimbra M,Vieira FQ,et al.Expression of histone methyltransferases as novel biomarkers for renal cell tumor diagnosis and prognostication[J].Epigenetics,2015,10(11):1033-1043.
24 Yan L,Ding B,Liu H,et al.Inhibition of SMYD2 suppresses tumor progression by down-regulating microRNA-125b and attenuates multi-drug resistance in renal cell carcinoma[J].Theranostics,2019,9(26):8377-8391.
25 Brown MA,Edwards MA,Alshiraihi I,et al.The lysine methyltransferase SMYD2 is required for normal lymphocyte development and survival of hematopoietic leukemias[J].Genes Immun,2020,21(2):119-130.
26 Oliveira-Santos W,Rabello DA,Lucena-Araujo AR,et al.Residual expression of SMYD2 and SMYD3 is associated with the acquisition of complex karyotype in chronic lymphocytic leukemia[J].Tumour Biol,2016,37(7):9473-9481.
27 Sakamoto LH,Andrade RV,Felipe MS,et al.SMYD2 is highly expressed in pediatric acute lymphoblastic leukemia and constitutes a bad prognostic factor[J].Leuk Res,2014,38(4):496-502.
28 Zipin-Roitman A,Aqaqe N,Yassin M,et al.SMYD2 lysine methyltransferase regulates leukemia cell growth and regeneration after genotoxic stress[J].Oncotarget,2017,8(10):16712-16727.
29 Sun JJ,Li HL,Ma H,et al.SMYD2 promotes cervical cancer growth by stimulating cell proliferation[J].Cell Biosci,2019,9:75.
30 石琳娜,隋红.原发性肝癌免疫检查点抑制剂治疗的进展与挑战[J].实用肿瘤学杂志,2020,34(6):560-564.
31 Zuo SR,Zuo XC,He Y,et al.Positive expression of SMYD2 is associated with Poor prognosis in patients with primary hepatocellular carcinoma[J].J Cancer,2018,9(2):321-330.

[1]	刘欣欣, 姚欣卉, 孙跃峰, 缪美琪, 陈晶. 乳腺癌微环境中趋化因子CCL20作用的研究进展[J]. 实用肿瘤学杂志, 2022, 36(3): 250-254.
[2]	郑艳丽, 贺建霞. 弥漫大B细胞淋巴瘤的DNA甲基化改变及治疗进展[J]. 实用肿瘤学杂志, 2022, 36(3): 259-262.
[3]	王雷雷, 陈辉. T1期高级别尿路上皮癌的治疗进展[J]. 实用肿瘤学杂志, 2022, 36(3): 283-287.
[4]	张宁, 蔺刘亚, 李思繁, 朱萌. miR-106a靶向调控TIMP2对人胃癌细胞增殖、转移及EMT的影响[J]. 实用肿瘤学杂志, 2022, 36(2): 105-110.
[5]	胡宗涛, 刘演, 高世乐, 甘晨, 张永康. 高剂量少分次放疗联合白蛋白结合型紫杉醇、替吉奥方案化疗在局部晚期胰腺癌患者中的临床疗效以及安全性评价[J]. 实用肿瘤学杂志, 2022, 36(2): 144-149.
[6]	吴芳芳, 郑桐森. 胆道恶性肿瘤辅助治疗的研究现状及展望[J]. 实用肿瘤学杂志, 2022, 36(2): 156-161.
[7]	刘雨, 俞星新, 耿志达, 陈政良, 惠鹏, 梁英健. 成纤维细胞在肝癌发生发展中的作用[J]. 实用肿瘤学杂志, 2022, 36(2): 167-172.
[8]	唐菊, 尚利华. BMI与免疫检查点抑制剂治疗恶性肿瘤疗效的关系[J]. 实用肿瘤学杂志, 2022, 36(2): 188-192.
[9]	王艳平, 邱琳, 武萌, 飒日娜. 2016年陕西省恶性肿瘤发病与死亡分析[J]. 实用肿瘤学杂志, 2022, 36(1): 1-6.
[10]	董丽娜, 梁田, 张献, 张广美. 卵巢癌对富脂大网膜的器官趋向性转移的研究进展[J]. 实用肿瘤学杂志, 2022, 36(1): 54-58.
[11]	史竞彤, 陈敏捷, 孙轶华. 恶性肿瘤来源外泌体在巨噬细胞M2极化中作用的研究进展[J]. 实用肿瘤学杂志, 2022, 36(1): 59-63.
[12]	孟鑫, 鲁金月, 张爱琳, 何录文. 藤梨根抗肿瘤药效物质和药理活性研究进展[J]. 实用肿瘤学杂志, 2022, 36(1): 69-73.
[13]	王洋, 李国东, 汤庆超, 刘明. 酸中毒在结直肠恶性肿瘤中的研究进展[J]. 实用肿瘤学杂志, 2022, 36(1): 74-78.
[14]	刘芮, 陈杨, 石青萍, 余秋丽, 朱云芳, 文洪梅. 云南省肿瘤登记地区2012—2016年甲状腺癌发病与死亡特征及时间趋势[J]. 实用肿瘤学杂志, 2021, 35(6): 489-494.
[15]	罗雯, 贾莉, 张佳文, 王冬杰, 孔英君. circRNA MYO1C对肺癌细胞自噬和肿瘤干细胞分化的影响[J]. 实用肿瘤学杂志, 2021, 35(6): 500-505.